Setipiprant, a selective oral antagonist of human CRTH2: Relative bioavailability of a capsule and a tablet formulation in healthy female and male subjects

Clinical Therapeutics

Volumn 35, Issue 11, 2013, Pages 1842-1848

  Baldoni, Daniela ^a   Mackie, Alison ^a   Gutierrez, Marcelo ^a   Theodor, Rudolf ^b   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b PHAROS GmbH   (Germany)

Author keywords

CRTH2; human pharmacokinetics; relative bioavailability; setipiprant

Indexed keywords

G PROTEIN COUPLED RECEPTOR; PROTEIN CRTH2; SETIPIPRANT; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG TOLERABILITY; FATIGUE; FEMALE; FLATULENCE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

CRTH2; HUMAN PHARMACOKINETICS; RELATIVE BIOAVAILABILITY; SETIPIPRANT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BIOLOGICAL AVAILABILITY; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NAPHTHALENES; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; TABLETS; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 84888000785     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2013.09.003     Document Type: Article

References (21)

1. P.J. Barnes New drugs for asthma Discov Med 4 2004 421 426
2. S.T. Holgate The epidemic of allergy and asthma Nature 402 6760 Suppl 1999 B2 B4
3. A. Valdenaire, J. Pothier, and D. Renneberg Evolution of novel tricyclic CRTH2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold Bioorg Med Chem Lett 23 2013 944 948
4. E. Kostenis, and T. Ulven Emerging roles of DP and CRTH2 in allergic inflammation Trends Mol Med 12 2006 148 158
5. S.L. Vinall, E.R. Townsend, and R. Pettipher A paracrine role for chemoattractant receptor-homologous molecule expressed on T helper type 2 cells (CRTH2) in mediating chemotactic activation of CRTH2+ CD4+ T helper type 2 lymphocytes Immunology 121 2007 577 584
6. F.G. Gervais, R.P. Cruz, and A. Chateauneuf Selective modulation of chemokinesis, degranulation, and apoptosis in eosinophils through the PGD2 receptors CRTH2 and DP J Allergy Clin Immunol 108 2001 982 988
7. K. Tanaka, H. Hirai, S. Takano, M. Nakamura, and K. Nagata Effects of prostaglandin D2 on helper t cell functions Biochem Biophys Res Commun 316 2004 1009 1014
8. L. Xue, A. Barrow, and R. Pettipher Interaction between prostaglandin D and chemoattractant receptor-homologous molecule expressed on Th2 cells mediates cytokine production by Th2 lymphocytes in response to activated mast cells Clin Exp Immunol 156 2009 126 133
9. L. Xue, S.L. Gyles, and F.R. Wettey Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells J Immunol 175 2005 6531 6536
10. S.L. Gyles, L. Xue, E.R. Townsend, F. Wettey, and R. Pettipher A dominant role for chemoattractant receptor-homologous molecule expressed on T helper type 2 (Th2) cells (CRTH2) in mediating chemotaxis of CRTH2+ CD4+ Th2 lymphocytes in response to mast cell supernatants Immunology 119 2006 362 368
11. H. Hirai, K. Tanaka, and O. Yoshie Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2 J Exp Med 193 2001 255 261
12. R. Pettipher The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses Br J Pharmacol 153 Suppl 1 2008 S191 S199
13. R. Pettipher, T.T. Hansel, and R. Armer Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases Nat Rev Drug Discov 6 2007 313 325
14. P. Schratl, E.M. Sturm, and J.F. Royer Hierarchy of eosinophil chemoattractants: role of p38 mitogen-activated protein kinase Eur J Immunol 36 2006 2401 2409
15. Fretz H, Valdenaire A, Pothier J, et al. Discovery of ACT-129968, a potent, selective, and oral CRTH2 receptor antagonist for the treatment of allergic diseases. Abstract presented at: 244th ACS National Meeting; August 19-23, 2012; Philadelphia, Pa
16. Sidharta PN, Diamant Z, Dingemanse J. Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist ACT-CRTH2 in healthy subjects. Abstract presented at: 38th Annual Meeting American College of Clinical Pharmacology; September 13-15, 2009; San Antonio, Tex
17. Diamant Z, Singh D, O'Connor BJ, et al. Effect of multiple-dose setipiprant, a selective oral CRTH2 antagonist, on allergen-induced airway responses in allergic asthmatic patients. Abstract presented at: American Thoracic Society International Conference; May 18-23, 2012; San Francisco, Calif
18. Clinical trial identifiers NCT01225315, NCT01241214, and NCT01484119. http://clinicaltrials.gov. Accessed September 1, 2013.
19. EMA. Guideline on validation of bioanalytical methods. November 2009. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/ 08/WC500109686.pdf. Accessed April 1, 2012.
20. FDA. Guidance for industry bioanalytical method validation. May 2001. http://wwwfdagov/downloads/Drugs//Guidances/ucm070107pdf. Accessed April 1, 2012.
21. S.A. Julious, and C.A. Debarnot Why are pharmacokinetic data summarized by arithmetic means? J Biopharm Stat 10 2000 55 71